Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma

Timothy P. C. Yeung, BSc,1,2,3 Slav Yartsev, PhD,1,3,4 Ting-Yim Lee, PhD,2,3,4,5,6 Eugene Wong, PhD,1,4,7 Wenqing He, PhD,8 Barbara Fisher, MD, FRCPC,1,4 Lauren L. VanderSpek, MD,1,4 David Macdonald, MD, FRCPC,1,4,9 & Glenn Bauman, MD, FRCPC,1,3,4

1London Regional Cancer Program, London Health Sciences Centre, Ontario, Canada
2Robarts Research Institute, The University of Western Ontario, Ontario, Canada
3Department of Medical Biophysics, The University of Western Ontario, Ontario, Canada
4Department of Oncology, The University of Western Ontario, London Health Sciences Centre, Ontario, Canada
5Department of Medical Imaging, The University of Western Ontario, London Health Sciences Centre, Victoria Hospital, Ontario, Canada
6Lawson Health Research Institute, St. Joseph’s Health Care London, Ontario, Canada
7Department of Physics and Astronomy, The University of Western Ontario, Ontario, Canada
8Department of Statistical and Actuarial Sciences, The University of Western Ontario, Ontario, Canada
9Department of Clinical Neurological Sciences, The University of Western Ontario, London Health Sciences Centre, University Hospital, Ontario, Canada

Keywords
18-Fluorodeoxyglucose PET, contrast enhancement, CT perfusion, malignant glioma, tumour progression

Correspondence
Glenn Bauman, London Regional Cancer Program, London Health Sciences Center, 790 Commissioners Road East, London, Ontario, Canada N6A 4L6.
Tel: 1 (519) 685-8500, ext. 53177; Fax: 1 (519) 685-8739; E-mail: glenn.bauman@lhsc.on.ca

Funding Information
This study was supported by grants from the Brain Tumour Foundation of Canada; the Canadian Institutes of Health Research (CIHR); the CIHR Strategic Training Program in Cancer Research and Technology Transfer (CaRITT); the Ontario Institute for Cancer Research and the Canadian Cancer Society (grant #700386).

Received: 12 September 2013; Revised: 21 November 2013; Accepted: 27 November 2013

Abstract

Introduction: This study aimed to explore the potential for computed tomography (CT) perfusion and 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting sites of future progressive tumour on a voxel-by-voxel basis after radiotherapy and chemotherapy. Methods: Ten patients underwent pre-radiotherapy magnetic resonance (MR), FDG-PET and CT perfusion near the end of radiotherapy and repeated post-radiotherapy follow-up MR scans. The relationships between these images and tumour progression were assessed using logistic regression. Cross-validation with receiver operating characteristic (ROC) analysis was used to assess the value of these images in predicting sites of tumour progression. Results: Pre-radiotherapy MR-defined gross tumour; near-end-of-radiotherapy CT-defined enhancing lesion; CT perfusion blood flow (BF), blood volume (BV) and permeability-surface area (PS) product; FDG-PET standard uptake value (SUV); and SUV: BF showed significant associations with tumour progression on follow-up MR imaging (P < 0.0001). The mean sensitivity (±standard deviation), specificity and area under the ROC curve (AUC) of PS were 0.64 ± 0.15, 0.74 ± 0.07 and 0.72 ± 0.12 respectively. This mean AUC was higher than that of the pre-radiotherapy MR-defined gross tumour and near-end-of-radiotherapy CT-defined enhancing lesion (both AUCs = 0.6 ± 0.1, P ≤ 0.03). The multivariate model using BF, BV, PS and SUV had a mean AUC of 0.8 ± 0.1, but this was not significantly higher than the PS only model. Conclusion: PS is the single best predictor of tumour progression when compared to other parameters, but voxel-based prediction based on logistic regression had modest sensitivity and specificity.

Journal of Medical Radiation Sciences 61 (2014) 4–13
doi: 10.1002/jmrs.37

© 2014 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Introduction

In malignant glioma, over 80% of tumour progression occurs within 2 cm of the original tumour site after radiotherapy and concurrent and adjuvant temozolomide chemotherapy. Radiological assessment of tumour progression is primarily based on gadolinium-enhanced magnetic resonance (MR) or iodinated contrast-enhanced computed tomography (CT). An increase in the size of the contrast-enhancing lesion is one of the criteria for diagnosing progression. However, early changes in contrast enhancement after treatment lack utility in identifying active tumour sites that are likely to persist after treatment.

Functional imaging is gaining popularity as it has demonstrated utility in differentiating tumour grade, predicting treatment response and survival and in identifying active tumour after treatment prior to progression. Pre-treatment functional imaging measurements of tumour perfusion and metabolism have been shown to predict survival in newly diagnosed and recurrent malignant glioma. Similarly, changes in blood flow (BF) and blood volume (BV) during radiotherapy have been shown to be predictive of survival. The use of multiparametric imaging data may have an added value for predicting survival. For example, tumour metabolism and BF were combined into a metric called the metabolism-flow ratio, and this was found to be predictive of poor survival in pancreatic cancer. Metabolism and BF are usually tightly coupled in normal tissue; however, an increase in metabolism in the presence of low BF may be indicative of a tumour’s adaptation to hypoxia. This suggests that the metabolism-flow ratio may be a valuable biomarker of hypoxia, which is associated with treatment resistance.

CT perfusion can simultaneously measure BF, BV and permeability-surface area product (PS) in brain tumours, and 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) is in routine clinical use for measuring tumour metabolism. The combination of FDG-PET and CT perfusion using a hybrid PET/CT scanner is a practical technique for assessing metabolism and perfusion in quick succession. This can also be used to calculate the metabolism-flow ratio, which circumvents the need for specialised synthesis capabilities to produce hypoxia tracers such as 18-Fluoro-azomycin arabinoside.

No functional imaging studies have been reported near the completion of radiotherapy as an attempt to detect residual malignant gliomas. This study investigated the associations between the pre-radiotherapy gross tumour as defined on contrast-enhanced MR, near-end-of-radiotherapy enhancing lesion as defined on contrast-enhanced CT, near-end-of-radiotherapy CT perfusion and FDG-PET parameters with post-treatment MR-defined tumour progression. We then assessed the value of using these imaging parameters for predicting post-treatment MR-defined tumour progression. Therefore, the goal of this study was to assess whether functional imaging has the potential in predicting sites of future progressive tumour on a voxel-by-voxel basis after radiotherapy and chemotherapy. This can help identify biologically significant volumes of disease present at the end of conventional radiotherapy that could serve as a target for treatment intensification.

Methods

Patients

All study procedures were approved by Institutional Research Ethics Board. Patients with newly diagnosed malignant glioma were prospectively recruited to the study with informed consent prior to the last week of radiotherapy. The inclusion criteria were: (1) at least 18 years of age, (2) histologically confirmed malignant glioma, (3) Karnofsky Performance Status ≥60, (4) no previous cranial radiotherapy and (5) pre-radiotherapy MR were performed within 12 weeks of radiotherapy treatment planning. Recurrent gliomas, multiple intracranial lesions, or patients that were not suitable for radical radiotherapy (40–60 Gy in 15–30 fractions) were excluded.

Multi-modality imaging schedule

After surgery but before radiotherapy, each patient underwent a standard MR imaging comprised of at least one series of T1- and T2-weighted images using a 1.5 T MR scanner (Signa Excite, General Electric Medical Systems, Milwaukee, WI). This MR scan was performed within 12 weeks of the treatment planning CT. Contrast-enhanced T1-weighted images were acquired using a fast spoiled gradient echo sequence (repetition time = 10 msec, echo time = 4 msec and flip angle = 15°) after an intravenous injection of gadopentetate dimeglumine (0.2 mL/kg; Magnevist; Berlex Laboratories, Wayne, NJ).

A FDG-PET and CT perfusion scan was performed during the final week of radiotherapy using a hybrid PET/CT scanner (Discovery VCT, General Electric Healthcare, Waukesha, WI). After an intravenous injection of FDG (385 MBq), positron emission data were collected in list mode for 60 min and binned into 5 min frames in the last 40 min. Each PET data set consisted of 47 axial PET images with a 3.26 mm slice thickness and a 26 cm axial field of view (FOV).

The FDG-PET CT attenuation correction maps in the FDG-PET study were used to select eight 5 mm sections to maximally cover the tumour for a 150 sec two-phase
CT perfusion scan. A non-ionic contrast bolus (Omnipaque, General Electric Healthcare, Princeton, NJ, 300 mg iodine per mL, 0.8 mL/kg of body weight) was injected at a rate of 2–4 mL/sec at 3–5 sec before the start of the scan. While the selected brain sections were scanned continuously for 45 sec and the images reconstructed at 1-sec intervals during the first phase, the same sections were scanned once every 15 sec for seven times during the second phase. The scanning parameters for both phases were 80 kVp, 190 mA, 1 sec per rotation and a 25-cm FOV.

Post-radiotherapy follow-ups were both clinical and radiological. Routine MR images were obtained at 4–6 weeks post-radiotherapy and every 3 months thereafter, and were reviewed by a neuro-oncologist or radiation oncologist. Tumour progression was defined as a continual enlargement of new enhancing lesion (without subsequent resolution) on serial MR imaging along with deterioration of clinical signs and symptoms.2

**Image processing**

CT perfusion images were analysed using the prototype version of CT Perfusion 4D (Advantage Windows, GE Healthcare, Waukesha, WI). Arterial and venous time-attenuation curves were measured from an anterior cerebral artery and the posterior superior sagittal sinus respectively. BF, BV and PS maps were calculated by deconvolving the arterial time-attenuation curve with the tissue time-attenuation curve from 2 × 2 voxel blocks of CT images.12 The CT images were averaged together to produce average CT images, which have better grey and white matter contrast than conventional contrast-enhanced CT images.

Software provided with the PET/CT scanner was used to correct the PET emission data for random and scatter coincidences, dead time and attenuation. PET images from the last 5 min bin were rigidly co-registered with the average CT using the 3D Slicer software.13 The registered PET voxel values were converted to standard uptake values (SUV) corrected for body surface area.14 SUV maps were divided by the BF maps to generate SUV:BF ratio maps.

Gadolinium-enhanced T1-weighted MR images from pre-radiotherapy and at progression were rigidly co-registered with the near-end-of-radiotherapy average CT. All images (MR and average CT) and functional maps (CT perfusion and PET SUV) were then resampled to 170 × 170 voxels to minimise registration error. From here on, the contrast-enhancing lesion in the pre-radiotherapy T1-weighted MR lesion is the gross tumour, the contrast-enhancing lesion on the average CT acquired at the last week of radiotherapy is the near-end-of-radiotherapy enhancing lesion, and the contrast-enhancing lesion on follow-up T1-weighted MR at the time of progression is the progressive tumour. Contours around the pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and progressive tumour were delineated by a radiation oncologist (G. B.). Table 1 summarises the labelling and time of acquisition of the images.

**Logistic regression**

A custom MATLAB (MathWorks Incorporated, Natick, MA) program was developed for this analysis. A 2-cm bounding box around the union of the pre-radiotherapy gross tumour and the progressive tumour was created to reduce the amount of information for analysis for each patient. Major blood vessels, surgical cavities, ventricles and voxels outside the bounding box were excluded. Each voxel inside the bounding box was assigned three binary statuses: pre-radiotherapy gross tumour (yes/no), near-end-of-radiotherapy enhancing lesion (yes/no) and progressive tumour (yes/no). Logistic regression was used to assess the association between tumour progression and the following sets of independent imaging variables: (1)

| Table 1. Summary of images acquired in this study. |
|-----------------------------------------------|
| **Name** | **Type of image(s)** | **Image signal** | **Time of acquisition** |
| Gross tumour | T1-weighted MR | Gadolinium enhancement | Post-surgery/biopsy and pre-radiotherapy (must be within 12 weeks of treatment planning CT) |
| Near-end-of-radiotherapy enhancing lesion | Average CT | Iodine enhancement (HU) | Last week of radiotherapy |
| BF | BF map | mL/min per 100 g | Last week of radiotherapy |
| BV | BV map | mL/100 g | Last week of radiotherapy |
| PS | PS map | mL/min per 100 g | Last week of radiotherapy |
| PET | SUV map | FDG uptake | Last week of radiotherapy |
| Progressive tumour | T1-weighted MR | Gadolinium enhancement | Time of progression based on routine clinical and radiological follow-up assessments (4–6 weeks post-radiotherapy and every 3 months after) |

MR, magnetic resonance; CT, computed tomography; BF, blood flow; BV, blood volume; PS, permeability-surface area product; PET, positron emission tomography; SUV, standard uptake value; FDG, 18-Fluorodeoxyglucose.
pre-radiotherapy gross tumour, (2) near-end-of-radiotherapy enhancing lesion, (3) BF, BV, PS and SUV and (4) BV, PS, SUV:BF. The last regression was used to investigate the association between tumour progression and SUV:BF as a marker of hypoxia. The strength of association between each parameter and progressive tumour status was evaluated by the odds ratio. Odds ratios were converted to probabilities of recurrence for easier interpretations.

Cross-validation

Leave-one-out cross-validation was used to assess the value of using different imaging parameters to predict tumour progression. Each round of cross-validation used one patient data set as the validation set and the data sets from the other patients as the training set. Probability maps of progression for an individual patient (i.e. the validation set) were calculated using the logistic regression equation from the training set. We first considered seven single variable models: (1) Pre-radiotherapy gross tumour, (2) Near-end-of-radiotherapy enhancing lesion, (3) BF, (4) BV, (5) PS, (6) SUV and (7) SUV:BF. We then considered two multivariate models: (1) BV, PS, SUV:BF and (2) BF, BV, PS and SUV. Using receiver operating characteristic (ROC) analysis, the area under the ROC (AUC) curve was calculated. The optimal sensitivity and specificity was calculated using the Youden Index, which is the probability threshold that maximises the sum of sensitivity and specificity for all possible probabilities from 0% to 100%.

Statistical analysis

Pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and progressive tumour volumes within the 4 cm CT perfusion scan length were compared using the Wilcoxon signed-rank test. AUCs of the different logistic models were compared using the Friedman test followed by the Wilcoxon signed-rank test. Models with AUCs that are significantly higher than the AUCs of the pre-radiotherapy gross tumour and end-of radiotherapy enhancing lesion were reported. All statistical tests were done using SPSS version 19.0 (SPSS Incorporated, Chicago, IL), and P-values <0.05 were considered significant.

Results

Ten patients with newly diagnosed malignant glioma were prospectively recruited to the study between the years 2008 and 2011. After surgery, all patients underwent radiotherapy (60 Gy in 30 fractions) with concurrent and adjuvant temozolomide chemotherapy. Patient characteristics are listed in Table 2. Tumour progression with no evidence of necrosis was histopathologically confirmed in two patients (Patient 9 and 10 in Table 2); the remaining patients had tumour progression defined on clinical and imaging grounds only.

The mean volumes ± standard deviation (SD) of pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and the progressive tumour within the CT perfusion scan volume were 10.8 ± 11.1, 14.1 ± 20.8 and 16.1 ± 18.0 cm³ respectively. The differences in

### Table 2. Patient characteristics.

| Patient no. | Age | WHO grade | Tumour location | Type of resection | Months between radiotherapy and appearance of progressive tumours | Site of tumour progression | Treatment | Steroid use | Survival status |
|-------------|-----|-----------|----------------|-------------------|---------------------------------------------------------------|-----------------------------|-----------|-------------|----------------|
| 1           | 36  | 3         | Left frontal temporal | Partial           | 8.6                                                          | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 2           | 47  | 4         | Left parietal         | Near-total        | 12.0                                                         | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 3           | 55  | 4         | Left temporal         | Partial           | 2.3                                                          | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 4           | 37  | 3         | Left frontal temporal | Partial           | 8.4                                                          | In-field and Out-of-field   | RT, TMZ   | No          | Deceased       |
| 5           | 50  | 4         | Left frontal lobe     | Near-total        | 5.0                                                          | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 6           | 71  | 4         | Right temporal parietal | Biopsy           | 2.1                                                          | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 7           | 71  | 4         | Left frontal          | Biopsy           | 4.3                                                          | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 8           | 61  | 4         | Left posterior frontal parietal inter-axial tumour | Near-total        | 14.8                                                         | In-field                    | RT, TMZ   | Yes         | Deceased       |
| 9           | 60  | 4         | Left frontal parietal | Partial           | 11.0                                                         | In-field                    | RT, TMZ   | Yes         | Alive          |
| 10          | 54  | 4         | Left temporal         | Biopsy           | 15.6                                                         | In-field                    | RT, TMZ   | Yes         | Alive          |

WHO, World Health Organisation; RT, radiotherapy; TMZ, concurrent + adjuvant temozolomide.

1In-field = within 2 cm of the primary contrast-enhancing tumour.

2Out-of-field = beyond 2 cm of the primary contrast-enhancing tumour.
volumes were not significant ($P > 0.05$). Figure 1 displays the images of patient 3.

**Voxel-based logistic regression**

When compared with normal brain tissue, the pre-radiotherapy gross tumour and the near-end-of-radiotherapy enhancing lesion had odds ratios of 12.7 (95% confidence interval [CI], 12.1–13.4) and 43.3 (95% CI, 41.4–45.3), respectively, for tumour recurrence. These odds can be expressed as recurrence probabilities of 54.4% and 69.8% respectively. Multivariate logistic regression showed that the odds of tumour progression increased with lower BF, BV and SUV; and with higher PS and SUV:BF ($P < 0.0001$) (Table 3).

**Cross-validation**

The AUCs for the three models (1) PS alone, (2) BV, PS, SUV:BF and (3) BF, BV, PS and SUV were 0.72 ± 0.12, 0.74 ± 0.13 and 0.77 ± 0.11 respectively. These AUCs were significantly higher than the AUCs of the pre-radio-

![Figure 1. Pre-radiotherapy gross tumour (T1-weighted MR), near-end-of-radiotherapy enhancing lesion (averaged CT) and progressive tumour (T1-weighted MR); and the corresponding parametric maps of blood flow (BF), blood volume (BV), permeability-surface area (PS) product, standard uptake value (SUV) and SUV:BF acquired using CT perfusion and FDG-PET. Blue outlines show the contrast-enhancing lesions delineated by a radiation oncologist. Yellow outline is the 2-cm bounding box that was set for performing logistic regression. MR, magnetic resonance; CT, computed tomography; FDG-PET, 18-Fluorodeoxyglucose positron emission tomography.](image)
therapy gross tumour and near-end-of-radiotherapy enhancing lesion (Friedman $P < 0.001$; Wilcoxon signed-rank $P \leq 0.03$), which were $0.64 \pm 0.14$ and $0.65 \pm 0.14$ respectively. Although the AUCs of the two multivariate models were higher than that of PS, the differences were not statistically significant ($P > 0.05$). Table 4 shows model pairs that are significantly higher than the pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion. The model using PS alone had a sensitivity and specificity of $0.6\pm0.1$ and $0.7\pm0.1$, respectively (Fig. 2). The model using BF, BV, PS and SUV had the highest combination of sensitivity and specificity ($0.7\pm0.1$ and $0.7\pm0.1$). Probability maps of progression were generated using these logistic models, examples of probability maps for patient 3 are shown in Figure 3.

### Discussion

We investigated whether near-end-of-radiotherapy CT perfusion and FDG-PET can add value to the assessment of malignant glioma in terms of predicting voxels that are likely to progress after treatment. PS alone was found to be the best predictor of tumour progression when compared to other CT perfusion and FDG-PET parameters; however, voxel-based prediction of progression had only modest sensitivity and specificity.

PS describes the unidirectional flow of contrast as it leaks from the intravascular space into the interstitial space (i.e. brain parenchyma). It is not the same as contrast enhancement because it quantitatively measures the rate of contrast extravasation. In this study, not only did PS show a significant association with progressive tumour but it had a higher AUC than the pre-radiotherapy gross tumour and near-end-of-radiotherapy enhancing lesion for identifying tumour voxels that are more likely to progress. This suggests that PS adds value to contrast enhancement in determining active tumour regions after treatment, and also provides corroborating evidence to support that PS is associated with tumour aggressiveness. PS can be a biomarker of tumour aggressiveness because of the underlying pathological aspect that it represents. PS has larger value in high-grade gliomas compared to low-grade gliomas, which is important for prognosis. It also showed correlations with aggressive phenotypes including microvascular cellular proliferation and the expression of pro-angiogenic genes. Finally, PS has been used to distinguish true tumour progression from treatment effect like treatment-induced necrosis.

### Table 3. Multivariate logistic regression.

| Model | Parameter | $P$ | $^{1}$Regression coefficients ($\beta$) | Odds ratio ($e^\beta$) | 95% confidence interval | Probability (%) |
|-------|-----------|-----|----------------------------------------|------------------------|-------------------------|-----------------|
| 1     | BV        | $<0.0001$ | $-0.15$ | 0.86 | 0.84 | 0.87 | 7.1 |
|       | PS        | $<0.0001$ | $0.41$ | 1.51 | 1.49 | 1.52 | 11.9 |
|       | SUV:BF    | $<0.0001$ | $2.63^{2}$ | 13.88 | 11.38 | 16.94 | 55.4 |
|       | Constant  | $<0.0001$ | $-2.41$ | 0.09 | 0.09 | 0.09 | 8.2 |
| 2     | BF        | $<0.0001$ | $-0.01$ | 0.99 | 0.99 | 0.99 | 23.1 |
|       | BV        | $<0.0001$ | $-0.07$ | 0.93 | 0.91 | 0.95 | 22.1 |
|       | PS        | $<0.0001$ | $0.39$ | 1.48 | 1.47 | 1.50 | 31.0 |
|       | SUV       | $<0.0001$ | $-0.93$ | 0.39 | 0.37 | 0.41 | 10.7 |
|       | Constant  | $<0.0001$ | $-1.19$ | 0.30 | 0.29 | 0.32 | 23.3 |

1 Degrees of freedom = 128,330.

2 An increase in SUV:BF value by 0.01 was associated with an odds ratio = 1.03; this corresponded to a probability of 8.4%.

### Table 4. Statistical differences in area under the receiver operating characteristics curve.

| Model 1 | Model 2 | % Difference = \(\frac{(model 2 - model 1) \times 100}{(model 1)\times100}\) | $\pm SD$ | $P$ |
|---------|---------|-------------------------------------------------|---------|-----|
| Pre-radiotherapy gross tumour | PS | 14.2 | 18.1 | 0.03 |
| | BV, PS, SUV:BF | 16.4 | 18.6 | 0.03 |
| | BF, BV, PS, SUV | 21.4 | 18.6 | $<0.01$ |
| End-of-radiotherapy enhancing lesion | PS | 12.7 | 10.7 | 0.02 |
| | BV, PS, SUV:BF | 15.4 | 16.7 | 0.03 |
| | BF, BV, PS, SUV | 21.1 | 20.4 | 0.02 |
| PS | BV, PS, SUV:BF | 2.1 | 7.2 | 0.29 |
| PS | BF, BV, PS, SUV | 7.5 | 15.9 | 0.29 |

SD, standard deviation; PS, permeability-surface area product; BV, blood volume; SUV, standard uptake value; BF, blood flow.
The observation that both lower BF and BV showed significant associations with tumour progression is noteworthy. A lower BF and BV may suggest resistance to therapy due to the presence of hypoxia. In support of this, dynamic susceptibility contrast MR studies at pre- and mid-radiotherapy showed that a drop in relative BF and BV were predictors of poor survival.5,7 However, the associations observed in this study were obtained from one time point only, and they do not suggest a causal relationship with progression.

We found that a lower SUV, when considering the entire tumour, is associated with an increased risk of progression. This is contrary to studies that showed an increased FDG uptake is associated with poor survival in patients at various stages of treatment or in patients with recurrent tumours.7,22 In these prior studies, FDG uptake in the hypermetabolic region was used to assess correlation with survival. This usually coincides with the contrast-enhancing region of the tumour where the perfusion is high; hence, an FDG delivery was unimpeded. Our results suggest that when considering the tumour as a whole, a lower FDG uptake is associated with higher odds of progression. A low FDG uptake does not necessarily infer a lack of metabolic demand. We instead showed a higher SUV:BF ratio was associated with an increased risk of recurrence, which suggests that a low SUV was due to poor delivery resulting in uncoupling between metabolism and perfusion. This is consistent with PET-based measure of SUV:BF in pancreatic cancer in which a higher SUV:BF was associated with poor survival.10 These observations provide evidence to support the Warburg Effect hypothesis.10,11 Cancer cells can maintain anaerobic respiration to keep up with its metabolic demand under hypoxic stress and can be therapeutically resistant. This could lead to tumour regions that remain active despite treatment.

Some limitations of this study must be considered. Although the AUCs of the multivariate models were higher than those of the univariate PS model, we were unable to demonstrate the statistical significance of multivariate models superiority. A larger sample size is required to determine whether (1) BF, BV, PS and SUV and (2) BV, PS and SUV:BF can provide more information than PS alone for identifying tumour regions that are likely to progress. Other radiotracers with a higher tumour-to-background ratio in the brain can improve the detection of residual tumour at the end of radiotherapy. For example, both 3′-Deoxy-3′-18F-fluorothymidine (FLT)23 and 11C-methionine PET24 were reported to be more sensitive than FDG in evaluating progressive tumours. Deformable registration could potentially improve the quality of registration. Most deformation of the tumour would occur from before and after surgery. This study used only post-surgery images; thus, physical deformation of the tumour is minimal. In addition, the majority of patients received dexamethasone during radiotherapy, which could decrease tumour permeability resulting in less oedema and hence less deformation.25 The use of dexamethasone can also decrease cerebral glucose metabolism.26,27 The effect of dexamethasone on glucose metabolism is global rather than localised; it is unlikely to affect the current results because the logistic regression is based on imaging data obtained from both the normal brain and tumour tissues.
Finally, we focused our investigation on the tumour site and its immediate surroundings, the potential effects of radiation on normal brain tissue perfusion and metabolism were not investigated in detail. A small radiation dose-dependent relationship (<10%) was observed for both brain tissue metabolism and perfusion. We evaluated the relationship between normal brain tissue BF, BV and PS with radiation dose in seven patients and did not find a significant relationship (data not shown). Thus, the effect of radiation on normal tissue BF, BV and PS is unlikely to affect the current results.

Conclusions

We developed a technique for voxel-wise analysis of CT perfusion and FDG-PET images acquired at the end of radiotherapy for patients treated for malignant glioma. On the basis of our analysis, near-end-of-radiotherapy PS was the best predictor of tumour progression on a voxel-by-voxel basis when compared to other CT perfusion and FDG-PET parameters. However, voxel-based analysis had only modest sensitivity and specificity. Exploration of these findings among a larger patient cohort would help confirm the value of PS imaging in predicting recurrence and in confirming the trend towards improved prediction with multivariate imaging data.

Acknowledgements

We thank Lorraine Hewett and Debra Dentelbeck for managing patient information and Michael Roes for examining the relationship between blood flow and radiotherapy dose.

Conflict of Interest

Dr. Ting-Yim Lee licenses CT Perfusion software to and receives funding from GE Healthcare.

References

1. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA, Korones DN. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78: 1147–55.
2. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963–72.

3. Peet AC, Arvanitis TN, Leach MO, Waldman AD. Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol 2012; 9: 700–11.

4. Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: Long-term follow-up study. AJNR Am J Neuroradiol 2008; 29: 1505–10.

5. Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: Ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009; 30: 681–8.

6. Colavolpe C, Metellus P, Mancini J, Barrie M, Béquet-Boucard C, Figarella-Branger D, Mundler O, Chinot O, Guedj E. Independent prognostic value of pre-treatment 18-FDG-PET in high grade gliomas. J Neurooncol 2012; 107: 527–35.

7. Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 2012; 14: 649–57.

8. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011; 17: 4751–60.

9. Galbán CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009; 15: 572–6.

10. Komar G, Kauhanen S, Liukko K, Seppänen M, Kajander S, Ovaska J, Nuutila P, Minn H. Decreased blood flow and metabolism in recurrent/progressive glioblastoma: A feasibility study. J Neurooncol 2012; 107: 527–35.

11. Miles KA, Williams RE. Warburg revisited: Imaging tumour blood flow and metabolism. Cancer Imaging 2008; 8: 81–6.

12. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med 2003; 47: 171–87.

13. Pieper S, Lorensen B, Schroeder W, Kikinis R. The NA-MIC Kit: ITK, VTK, pipelines, grids and 3D slicer as an open platform for the medical image computing community. Proc 3rd IEEE Int Symp Biomed Imaging: From Nano Macro 2006; 1: 698–701.

14. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000; 27: 647–55.

15. Bewick V, Cheek L, Ball J. Statistics review 14: Logistic regression. Crit Care 2005; 9: 112–8.

16. Bewick V, Cheek L, Ball J. Statistics review 13: Receiver operating characteristic curves. Crit Care 2004; 8: 508–12.

17. Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, Patel SC, Ewing J, Mikkelson T. Quantitative estimation of permeability surface-area product in astroglial brain tumours using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008; 29: 694–700.

18. Jain R, Gutierrez J, Narang J, Scarpase L, Schultz LR, Lemke N, Patel SC, Mikkelson T, Rock JP. In vivo correlation of tumour blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011; 32: 388–94.

19. Jain R, Poisson L, Narang J, Scarpase L, Rosenblum ML, Rempel S, Mikkelson T. Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: A feasibility study. AJNR Am J Neuroradiol 2012; 33: 1343–8.

20. Jain R, Narang J, Schultz L, Scarpase L, Saksena S, Brown S, Rock JP, Rosenblum M, Gutierrez J, Mikkelson T. Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: Can these add to other perfusion parameters in differentiating from recurrent/progressive tumours? AJNR Am J Neuroradiol 2011; 32: 658–63.

21. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003; 64: 227–37.

22. Santra A, Kumar R, Sharma P, Bal C, Jula PK, Malhotra A. F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: A prospective study. Neuroradiology 2011; 53: 1017–24.

23. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liu L, Misichel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 2005; 46: 945–52.

24. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012; 37: 158–63.

25. Yeung WT, Lee TY, Del Maestro RF, Kozak R, Bennett J, Brown T. Effect of steroids on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography. J Neurooncol 1994; 18: 53–60.

26. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in
patients with brain tumors: An effect of corticosteroids. 
*J Neurosurg* 1995; 83: 657–64.

27. Brock CS, Meikle SR, Price P. Does fluorine-18 
fluorodeoxyglucose metabolic imaging of tumours benefit 
oncology? *Eur J Nucl Med* 1997; 24: 691–705.

28. Hahn CA, Zhou SM, Raynor R, et al. Dose-dependent 
effects of radiation therapy on cerebral blood flow, 
metabolism, and neurocognitive dysfunction. *Int J Radiat 
Oncol Biol Phys* 2009; 73: 1082–7.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Video S1.** A dynamic series of CT perfusion images from which the maps of blood flow (BF), blood volume (BV), and permeability-surface area (PS) product were calculated from.